Wild dengue virus types 1, 2 and 3 viremia in rhesus monkeys

AUTOR(ES)

Freire, MS, Marchevsky, RS, Almeida, LFC, Yamamura, AMY, Caride, EC, Brindeiro, PA, Motta, MCA, Nogueira, RMR, Kubelka, CF, Bonaldo, MC, Galler, R

FONTE

Memórias do Instituto Oswaldo Cruz

DATA DE PUBLICAÇÃO

16/02/2007

RESUMO

Among the flaviviruses, dengue, with its four serotypes, has spread throughout the tropics. The most advanced vaccines developed so far include live attenuated viruses, which have been tested in humans but none has been licensed. Preclinical testing of dengue vaccine candidates is performed initially in mice and in nonhuman primates. In the latter the main criteria used to assay protection are neutralizing antibodies elicited by the vaccine candidate and the magnitude and duration of peripheral viremia upon challenge of previously immunized animals. Towards the identification of wild-type viruses that could be used in challenge experiments a total of 31 rhesus monkeys were inoculated subcutaneously of wild dengue types 1, 2, and 3 viruses. The viremia caused by the different viruses was variable but it was possible to identify dengue viruses useful as challenge strains.

Documentos Relacionados

• Dengue-2 Vaccine: Viremia and Immune Responses in Rhesus Monkeys
• Sensitive plaque neutralization assay for parainfluenza virus types 1, 2, and 3 and respiratory syncytial virus.
• Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.
• Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys
• Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.